Risk factor
Very high price volatility
Very poor trading liquidity
Weak & very vulnerable to price shocks
Profitability factor
Very low or no dividends
Very poor margins and returns
Overvalued vs peers
Risk / Profitability
Risk: High
Profitability: Poor
Risk factor
Very high price volatility
Very poor trading liquidity
Weak & very vulnerable to price shocks
Profitability factor
Very low or no dividends
Very poor margins and returns
Overvalued vs peers
$ 2.25
About
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It...
About
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious...
